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Considerations for the use of medical devices in dermatology
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Over the past several decades, there has been an 
explosion of medical devices introduced to the world 
of aesthetics. Although they each have intended 
purposes, the research supporting their claims is of 
variable quality. They are generally marketed with 
an overly optimistic assurance of promise. Although 
the Food and Drug Administration (FDA) plays an 
important role in establishing safety, there is less of 
an emphasis on efficacy. Thus, physicians are often 
handed the obligation of evaluating these devices in 
their clinical practices with only limited evidence of 
quality science and proof of benefit. Clearly, this is not 
always the case, but it is not unusual that clinicians 
will elaborate on the relative benefits (or lack thereof ) 
of a particular device after having had extensive 
clinical experience. It is therefore important that 
laser surgeons examine manufacturers’ supporting 
data, decipher their claims, and have a thorough 
understanding of any bias at play among key opinion 
leaders (physician investigator-industry relationship) 
in order to deliver high-quality, patient-centered, 
and cost-effective care.
The use of medical devices for specific indications 
would ideally be determined with the assistance of 
data from long-term, high-quality research studies. 
However, device manufacturers are generally 
small-cap companies without the deep pockets 
to perform extended multi-center studies that are 
characteristic of larger pharmaceutical corporations. 
Holding them to similar standards would endanger 
their tremendous ingenuity and agility. With the 
FDA’s Section 510(k) route, companies can submit 
information to establish that their devices are 
‘substantially equivalent’ to those that are currently 
marketed and subsequently receive clearance for 
use [1]. As a result, the laser surgeon is often left with 
some doubt as to whether or not to recommend 
treatments based on this less rigorous analysis. One 
such example would be the recently introduced 
robotic hair transplant system, which was cleared 
by the FDA through the 510(k) route. Although 
revolutionary and groundbreaking compared to 
former manual techniques, limited studies exist and 
few clinicians possess familiarity with the device. In 
situations like this, specialized experts should be 
called upon to fill the gap between the literature and 
clinical practice. Clinicians are encouraged to seek 
guidance from those who are more experienced 
before attempting to use any of the newer devices.
Abstract
This manuscript addresses the significant 
considerations concerning the development and 
use of medical devices in dermatology. With the 
rapidly growing demand and booming market 
for medical devices, especially lasers, it is crucial 
that dermatologists become familiar with the 
nuances associated with supporting clinical studies, 
consumer-driven marketing strategies, and the 
complex relationships that exist between physicians, 
industry, and consumers. An examination of these 
relationships includes an overview of the potential 
biases pertaining to advisory panels and treating 
clinicians. The aim of this paper is to serve as an 
introduction to the background of medical devices 
and to offer dermatologists important information 
on what should be considered before recommending 
treatment.
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Manufacturers rely heavily on consumer-driven 
marketing strategies in an effort to up-sell the use 
of their medical products [2]. Moreover, the media 
quickly follows their marketing, which is generally 
ahead of the science. In the aesthetic realm, 
advertisements often provide illusions of painless, 
quick cures with the promise of ageless beauty. This 
can create unrealistic expectations, and in the event 
that these expectations are unmet, patients may be 
unsatisfied with their care. Patients may be extremely 
impressed with devices (and in particular with 
‘lasers’) and ignore their potential risks, perceiving 
them to be technological miracles regardless of the 
specific end user [3]. One such example is the use of 
lasers for the treatment of onychomycosis. Although 
the marketing of these devices has suggested a rapid 
cure, this is quite contrary to its rather low efficacy 
and lengthy timeline needed to achieve clinical 
improvement. In such situations, it is important for 
clinicians to correct any misconceptions, inform 
patients of the available data, educate them on safety 
profiles, and offer realistic expectations for what can 
be achieved.
It is also important for us all to realize that bias is 
inherent. In this regard, there are three types of 
clinicians: 1) Those who are intimately associated with 
the development of a device, who are likely to be the 
best informed but also the most biased, 2) Those who 
are not involved in the development but possess a 
good understanding, who are less informed but also 
less biased, and 3) Those who are non-specialists 
lacking any familiarity, who are the least informed 
but also the least biased. Which category a clinician 
falls into may influence opinions and treatment 
recommendations. It is important that we include all 
three categories in our decision making.
Nevertheless, in an effort to reduce the negative 
effects of bias, disclosure of industry relationships 
is now required. The Sunshine Act, which was built 
into the Affordable Care Act, requires medical device 
manufacturers to disclose any financial exchanges 
with physicians and make this information available 
to the public [4]. Hailed as a groundbreaking 
undertaking, it was meant to promote transparency 
and empower patients. It has been speculated that 
overall physician payments have declined owing to 
the increased attention on marketing and payment 
practices. Although no solid data exists to determine 
its full effects, it was recently shown that plastic 
surgery exhibited the lowest prevalence (54.5%) 
of industry financial relationships following the 
enactment of the Sunshine Act when compared to 
other surgical subspecialties (57.9-87.8%, [5]). Though 
this may give comfort to some, others might lament 
the restrictions placed on our more scientifically-
inclined specialists as they are discouraged from 
performing much-needed clinical studies for fear of 
being labeled as mischievous by the public.
In this burgeoning market, dermatologists and plastic 
surgeons largely serve as gatekeepers between the 
medical device industry and consumers. Clinicians 
have professional, moral, and ethical obligations 
to deliver efficient, safe, and cost-effective care to 
patients. They deserve nothing less than a thorough 
analysis of any new device that comes to market. 
Those who are considered key opinion leaders 
and those who have investigated these devices 
must not deviate from objectivity when reporting 
the outcomes at our national meetings and in our 
specialty journals. An association with industry is 
to be encouraged, applauded, and appreciated, 
especially when the outcomes are modest and 
reported as such.
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